ADC Therapeutics (ADCT) Receivables: 2020-2023
Historic Receivables for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to $21.2 million.
- ADC Therapeutics' Receivables fell 15.10% to $21.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $142.9 million, marking a year-over-year increase of 81.41%. This contributed to the annual value of $73.8 million for FY2022, which is 137.93% up from last year.
- ADC Therapeutics' Receivables amounted to $21.2 million in Q3 2023, which was down 11.25% from $23.9 million recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Receivables registered a high of $73.8 million during Q4 2022, and its lowest value of -$1,000 during Q1 2020.
- Its 3-year average for Receivables is $22.2 million, with a median of $22.8 million in 2022.
- In the last 5 years, ADC Therapeutics' Receivables skyrocketed by 1,045,546.95% in 2022 and then fell by 15.10% in 2023.
- Quarterly analysis of 4 years shows ADC Therapeutics' Receivables stood at -$1,000 in 2020, then reached $31.0 million in 2021, then skyrocketed by 137.93% to $73.8 million in 2022, then fell by 15.10% to $21.2 million in 2023.
- Its last three reported values are $21.2 million in Q3 2023, $23.9 million for Q2 2023, and $24.0 million during Q1 2023.